T3	Method_cue 1723 1727	HRCT
T4	GGPs 1104 1108	SP-D
T5	GGPs 508 528	surfactant protein D
T11	Disorder 43 68	interstitial lung disease
T16	Subject 1505 1513	patients
T17	Subject 2401 2409	patients
T21	Disorder 2205 2225	advanced lung cancer
T23	Subject 853 861	patients
T27	Subject 1615 1623	patients
T30	Anatomical_entity 2253 2258	serum
T38	Subject 2136 2144	patients
T40	Subject 342 350	patients
T47	Method_cue 1206 1241	high resolution computed tomography
T57	Pharmacological_substance 689 705	cytotoxic agents
T58	Subject 1862 1870	patients
T62	GGPs 2324 2328	SP-D
T63	Subject 1321 1340	Thirty-six patients
T65	Subject 2226 2234	patients
T66	GGPs 530 534	SP-D
T74	Subject 569 577	patients
T77	Subject 1445 1453	patients
T78	Disorder 356 376	advanced lung cancer
T79	Disorder 101 121	advanced lung cancer
T81	Subject 645 649;671 679	1224 patients
T82	Disorder 1639 1662	diffuse alveolar damage
T87	Subject 2291 2301	Clinicians
T95	Method_cue 1243 1247	HRCT
T96	Anatomical_entity 2318 2323	serum
T102	Subject 1942 1950	patients
T106	Disorder 650 670	advanced lung cancer
T107	Subject 1280 1288	patients
T108	Subject 1404 1415	14 patients
N13	Reference T3 UMLS:C1512457	High Resolution Computed Tomography
N20	Reference T4 UMLS:C0084692	Pulmonary Surfactant-Associated Protein D
N27	Reference T5 UMLS:C0084692	Pulmonary Surfactant-Associated Protein D
N46	Reference T11 UMLS:C0206062	Lung Diseases, Interstitial
N64	Reference T16 UMLS:C0030705	Patients
N66	Reference T17 UMLS:C0030705	Patients
N82	Reference T21 UMLS:C0242379	Malignant neoplasm of lung
N88	Reference T23 UMLS:C0030705	Patients
N103	Reference T27 UMLS:C0030705	Patients
N121	Reference T30 UMLS:C0229671	Serum
N139	Reference T38 UMLS:C0030705	Patients
N145	Reference T40 UMLS:C0030705	Patients
N165	Reference T47 UMLS:C1512457	High Resolution Computed Tomography
N211	Reference T58 UMLS:C0030705	Patients
N226	Reference T62 UMLS:C0084692	Pulmonary Surfactant-Associated Protein D
N227	Reference T63 UMLS:C0030705	Patients
N238	Reference T65 UMLS:C0030705	Patients
N246	Reference T66 UMLS:C0084692	Pulmonary Surfactant-Associated Protein D
N270	Reference T74 UMLS:C0030705	Patients
N280	Reference T77 UMLS:C0030705	Patients
N285	Reference T78 UMLS:C0242379	Malignant neoplasm of lung
N289	Reference T79 UMLS:C0242379	Malignant neoplasm of lung
N298	Reference T81 UMLS:C0030705	Patients
N300	Reference T82 UMLS:C1262020	diffuse alveolar damage
N314	Reference T87 UMLS:C0871685	Clinician
N339	Reference T95 UMLS:C1512457	High Resolution Computed Tomography
N344	Reference T96 UMLS:C0229671	Serum
N358	Reference T102 UMLS:C0030705	Patients
N369	Reference T106 UMLS:C0242379	Malignant neoplasm of lung
N370	Reference T107 UMLS:C0030705	Patients
N372	Reference T108 UMLS:C0030705	Patients
T116	Disorder 158 184	Interstitial lung diseases
T128	Disorder 2150 2156	ILD-AA
N8	Reference T116 UMLS:C0206062	Lung Diseases, Interstitial
T10	Pharmacological_substance 196 213	anticancer agents
N9	Reference T10 UMLS:C0003392	Antineoplastic Agents
T132	Disorder 307 313	ILD-AA
T133	Disorder 593 599	ILD-AA
T134	Disorder 884 890	ILD-AA
T135	Disorder 1015 1021	ILD-AA
T136	Disorder 1188 1194	ILD-AA
T137	Disorder 1356 1362	ILD-AA
T138	Disorder 1424 1430	ILD-AA
T139	Disorder 2048 2054	ILD-AA
T140	Disorder 2195 2201	ILD-AA
T6	Disorder 215 221	ILD-AA
T43	Disorder 1304 1310	ILD-AA
T115	Disorder 1074 1080	ILD-AA
T117	Disorder 1125 1131	ILD-AA
T118	Disorder 2283 2289	ILD-AA
T119	GGPs 0 20	Surfactant protein-D
N23	Reference T119 UMLS:C0084692	Pulmonary Surfactant-Associated Protein D
T29	Pharmacological_substance 80 97	anticancer agents
N25	Reference T29 UMLS:C0003392	Antineoplastic Agents
T34	GGPs 442 496	sialylated carbohydrate antigen Krebs von den Lungen-6
N16	Reference T34 UMLS:C0057628	Mucin-1 protein
T59	GGPs 498 502	KL-6
N18	Reference T59 UMLS:C0057628	Mucin-1 protein
T120	GGPs 1095 1099	KL-6
N53	Reference T120 UMLS:C0057628	Mucin-1 protein
N48	Reference T57 UMLS:C0304497	Cytotoxic agent
T22	Subject 1584 1594	two groups
N50	Reference T22 UMLS:C1257890	Population Group
R1	Subject_Disorder Arg1:T40 Arg2:T78	
R2	Subject_Disorder Arg1:T81 Arg2:T106	
R3	Subject_Disorder Arg1:T63 Arg2:T137	
R4	Subject_Disorder Arg1:T38 Arg2:T128	
R5	Subject_Disorder Arg1:T65 Arg2:T21	
R6	Subject_Disorder Arg1:T107 Arg2:T43	
R7	Subject_Disorder Arg1:T74 Arg2:T133	
R8	Subject_Disorder Arg1:T23 Arg2:T134	
T12	Pharmacological_substance 710 769	epidermal growth factor receptor tyrosine kinase inhibitors
N52	Reference T12 UMLS:C1443775	Epidermal growth factor receptor inhibitor
T24	Positive_regulation 185 192	induced
E4	Positive_regulation:T24 Cause:T10 Theme:T116
N56	Reference E4 UMLS:C1879547	Activation action
T42	Positive_regulation 69 76	induced
E7	Positive_regulation:T42 Cause:T29 Theme:T11 disorder:T79
N59	Reference E7 UMLS:C1879547	Activation action
T48	Negative_regulation 759 769	inhibitors
E9	Negative_regulation:T48 Theme:T60 Cause:T12
N65	Reference E9 UMLS:C3463820	Inhibition
T60	GGPs 710 758	epidermal growth factor receptor tyrosine kinase
N67	Reference T60 UMLS:C3812393	ErbB Receptors
T64	Biological_process 233 248	adverse effects
E10	Biological_process:T64 Cause:E2
T7	Anatomical_entity 1200 1205	chest
N2	Reference T7 UMLS:C1527391	Anterior thoracic region
N1	Reference T6 UMLS:C0348822	Drug-induced interstitial lung disorder
N3	Reference T132 UMLS:C0348822	Drug-induced interstitial lung disorder
N4	Reference T133 UMLS:C0348822	Drug-induced interstitial lung disorder
N5	Reference T134 UMLS:C0348822	Drug-induced interstitial lung disorder
N6	Reference T135 UMLS:C0348822	Drug-induced interstitial lung disorder
N7	Reference T115 UMLS:C0348822	Drug-induced interstitial lung disorder
N11	Reference T117 UMLS:C0348822	Drug-induced interstitial lung disorder
N12	Reference T136 UMLS:C0348822	Drug-induced interstitial lung disorder
N14	Reference T43 UMLS:C0348822	Drug-induced interstitial lung disorder
N15	Reference T137 UMLS:C0348822	Drug-induced interstitial lung disorder
N17	Reference T138 UMLS:C0348822	Drug-induced interstitial lung disorder
N19	Reference T139 UMLS:C0348822	Drug-induced interstitial lung disorder
N21	Reference T128 UMLS:C0348822	Drug-induced interstitial lung disorder
N22	Reference T140 UMLS:C0348822	Drug-induced interstitial lung disorder
N24	Reference T118 UMLS:C0348822	Drug-induced interstitial lung disorder
T1	Biological_process 1171 1176	death
E1	Biological_process:T1 
N26	Reference E1 UMLS:C0011065	Cessation of life
T9	Correlation 1177 1184	related
E3	Correlation:T9 Theme:E1 Theme2:T136
N28	Reference E3 UMLS:C0332281	Associated with
T13	Biological_process 1416 1420	died
E5	Biological_process:T13 Cause:T138 Theme:T108
N29	Reference E5 UMLS:C0011065	Cessation of life
T18	Biological_process 1458 1462	died
E8	Biological_process:T18 Theme:T77
N30	Reference E8 UMLS:C0011065	Cessation of life
T20	Method_cue 1967 1988	Multivariate analysis
N32	Reference T20 UMLS:C0026777	Multivariate Analysis
T28	Artificial_process 869 878	diagnosed
E12	Artificial_process:T28 Theme:T134
N39	Reference E12 UMLS:C0011900	Diagnosis
T33	Artificial_process 578 587	diagnosed
E13	Artificial_process:T33 Theme:T133
N40	Reference E13 UMLS:C0011900	Diagnosis
T39	Artificial_process 1289 1298	diagnosed
E14	Artificial_process:T39 Theme:T43
N41	Reference E14 UMLS:C0011900	Diagnosis
T50	Artificial_process 1341 1350	diagnosed
E15	Artificial_process:T50 Theme:T137
N42	Reference E15 UMLS:C0011900	Diagnosis
T8	Artificial_process 252 270	anticancer therapy
E2	Artificial_process:T8 
N33	Reference E2 UMLS:C0920425	cancer therapy
T26	Biological_process 1059 1070	development
E6	Biological_process:T26 Theme:T115
N34	Reference E6 UMLS:C0699748	Pathogenesis
T37	Disorder 659 670	lung cancer
N35	Reference T37 UMLS:C0242379	Malignant neoplasm of lung
T53	Entity_Property 650 658	advanced
N36	Reference T53 UMLS:C0205179	Advanced phase
R12	member_of Arg1:T106 Arg2:T37	
T54	Disorder 110 121	lung cancer
N37	Reference T54 UMLS:C0242379	Malignant neoplasm of lung
T55	Disorder 365 376	lung cancer
N38	Reference T55 UMLS:C0242379	Malignant neoplasm of lung
T56	Entity_Property 101 109	advanced
N45	Reference T56 UMLS:C0205179	Advanced phase
T61	Entity_Property 356 364	advanced
N47	Reference T61 UMLS:C0205179	Advanced phase
R13	member_of Arg1:T79 Arg2:T54	
R14	member_of Arg1:T78 Arg2:T55	
T68	Entity_Property 2205 2213	advanced
N49	Reference T68 UMLS:C0205179	Advanced phase
T70	Disorder 2214 2225	lung cancer
N51	Reference T70 UMLS:C0242379	Malignant neoplasm of lung
R15	member_of Arg1:T21 Arg2:T70	
N54	Reference E10 UMLS:C0877248	Adverse event
T71	Artificial_process 680 688	received
E11	Artificial_process:T71 Theme:T81 Instrument:T57 Instrument2:T12
N55	Reference E11 UMLS:C1621583	Administer
R16	Subject_Disorder Arg1:T27 Arg2:T82	
T73	Artificial_process 2336 2348	chemotherapy
E17	Artificial_process:T73 Theme:T17
N60	Reference E17 UMLS:C0392920	Chemotherapy Regimen
T25	Disorder 233 248	adverse effects
N44	Reference T25 UMLS:C0877248	Adverse event
R17	member_of Arg1:T116 Arg2:T25	
